Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ronan Andrew McLaughlin"'
Autor:
David Mcmahon, Awab Hussein, Hunter Mangleburg, Aine Nichianain, Orla Fitzpatrick, Ronan Andrew McLaughlin, Michael R. Conroy, Sam Jonathan Marks, Jarushka Naidoo, William Grogan, Adrian Gerard Murphy, Oscar S. Breathnach, Bryan T. Hennessy, Patrick G. Morris
Publikováno v:
Journal of Clinical Oncology. 40:e14037-e14037
e14037 Background: (MGMT) promotor is prognostic and predictive of temozolomide (TMZ) benefit in newly diagnosed GBM. It has been suggested that MGMT methylation is associated with TMZ toxicity in some cancers such as melanoma but is not clearly defi
Autor:
Ronan Andrew McLaughlin, Desmond N. Carney, David O'Reilly, Waseem Darwish, Megan Greally, David McMahon, M. Higgins, Sonya Chew, Colum Dennehy, Maha Al Sendi, John McCaffrey, Hailey Kathryn Carroll, Mohammed Raza Khan, Hazel O Sullivan, Jane Sui, Catherine M. Kelly, Mairi Lucas
Publikováno v:
Irish Journal of Medical Science
Irish Journal of Medical Science (1971-)
Irish Journal of Medical Science (1971-)
Background The COVID-19 pandemic has resulted in radical changes in the delivery of healthcare worldwide. Our oncology service (at an Irish national cancer centre) rapidly transitioned to the use of telemedicine or virtual clinics (VC) to minimise po
The impact of the COVID-19 pandemic on oncology clinical trial recruitment in an Irish cancer center
Autor:
Linda Coate, Roshni Andrew Kalachand, Valerie Madigan, Maureen O'Grady, Greg Korpanty, Ronan Andrew McLaughlin, Nemer Osman, Thamir Mahgoub
Publikováno v:
Journal of Clinical Oncology. 39:e18756-e18756
e18756 Background: The COVID-19 pandemic has created unprecedented disruptions to cancer clinical trial research across the world due to a temporary global suspension of patients’ recruitment to cancer clinical trials. Access to clinical trials per
Autor:
Anne-Marie DeFrein, David McMahon, Dearbhaile Catherine Collins, David Edward O Reilly, Richard Martin Bambury, Cian Ronayne, B. Macanovic, Derek G. Power, Ronan Andrew McLaughlin
Publikováno v:
Journal of Clinical Oncology. 39:1-1
1 Background: Innovation in the treatment of genitourinary (GU) malignancies is accelerating, however, many of these new treatments are often not available for patients. We sought to investigate patient access, cost and value of new systemic anti-can
Autor:
Derek G. Power, Cian Ronayne, Dearbhaile Catherine Collins, David Edward O Reilly, Anne-Marie DeFrein, B. Macanovic, Seamus O'Reilly, Ronan Andrew McLaughlin, Richard Martin Bambury
Publikováno v:
Journal of Clinical Oncology. 39:469-469
469 Background: There are significant disparities in patient access to innovative cancer medicines internationally. We sought to describe global drug licensing developments in gastrointestinal (GI) oncology from 2010 – 2020. We compared US, Europea
Publikováno v:
Journal of Clinical Oncology. 39:136-136
136 Background: Colorectal cancer (CRC) is the 3rd most common malignancy in Ireland with over 2700 cases annually. Approximately 20% are diagnosed with stage IV disease. The aim of this study is to evaluate the response to chemotherapy at primary an
Autor:
Austin G. Duffy, John Aird, Nabila Al-Julandani, Michael W. Bennett, Catherine Weadick, Ronan Andrew McLaughlin, Megan Ramsey, Derek G. Power
Publikováno v:
Journal of Clinical Oncology. 39:236-236
236 Background: Gastric adenocarcinoma is the fourth most frequent cancer worldwide and the second leading cause of cancer deaths. According to The Cancer Genome Atlas (TCGA) 9% of gastric carcinomas are associated with Epstein-Barr Virus (EBV). EBV-